$647.09
0.01%
Nasdaq, Aug 29, 10:00 pm CET
ISIN
US45168D1046
Symbol
IDXX

IDEXX Laboratories Stock price

$647.09
+74.02 12.92% 1M
+209.98 48.04% 6M
+233.65 56.51% YTD
+159.81 32.80% 1Y
+298.04 85.39% 3Y
+256.03 65.47% 5Y
+575.62 805.40% 10Y
+631.18 3,966.55% 20Y
Nasdaq, Closing price Fri, Aug 29 2025
+0.06 0.01%
ISIN
US45168D1046
Symbol
IDXX

Key metrics

Basic
Market capitalization
$51.8b
Enterprise Value
$52.7b
Net debt
$939.2m
Cash
$164.6m
Shares outstanding
80.2m
Valuation (TTM | estimate)
P/E
53.2 | 50.3
P/S
12.8 | 12.0
EV/Sales
13.1 | 12.2
EV/FCF
68.1
P/B
35.5
Financial Health
Equity Ratio
48.4%
Return on Equity
55.7%
ROCE
59.6%
ROIC
34.3%
Debt/Equity
0.8
Financials (TTM | estimate)
Revenue
$4.0b | $4.3b
EBITDA
$1.4b | $1.5b
EBIT
$1.3b | $1.3b
Net Income
$985.7m | $1.0b
Free Cash Flow
$774.3m
Growth (TTM | estimate)
Revenue
6.7% | 10.8%
EBITDA
15.7% | 17.1%
EBIT
15.9% | 17.8%
Net Income
16.6% | 16.0%
Free Cash Flow
-7.7%
Margin (TTM | estimate)
Gross
61.5%
EBITDA
34.5% | 34.3%
EBIT
31.1%
Net
24.4% | 23.9%
Free Cash Flow
19.2%
More
EPS
$12.2
FCF per Share
$9.7
Short interest
3.0%
Employees
11k
Rev per Employee
$350.0k
Show more

Create a Free Account to create an IDEXX Laboratories alert.

Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.

IDEXX Laboratories Stock Analysis

Unlock Scores for Free

Analyst Opinions

21 Analysts have issued a IDEXX Laboratories forecast:

14x Buy
67%
7x Hold
33%

Analyst Opinions

21 Analysts have issued a IDEXX Laboratories forecast:

Buy
67%
Hold
33%

Financial data from IDEXX Laboratories

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
4,038 4,038
7% 7%
100%
- Direct Costs 1,553 1,553
4% 4%
38%
2,485 2,485
9% 9%
62%
- Selling and Administrative Expenses 997 997
0% 0%
25%
- Research and Development Expense 233 233
12% 12%
6%
1,393 1,393
16% 16%
34%
- Depreciation and Amortization 138 138
14% 14%
3%
EBIT (Operating Income) EBIT 1,255 1,255
16% 16%
31%
Net Profit 986 986
17% 17%
24%

In millions USD.

Don't miss a Thing! We will send you all news about IDEXX Laboratories directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

IDEXX Laboratories Stock News

Neutral
Seeking Alpha
25 days ago
Insmed, Intuitive Surgical, and IDEXX Laboratories were top contributors, driven by strong drug pipelines, innovation, and robust financial results. We exited UnitedHealth Group due to earnings misses, guidance cuts, and Medicare Advantage mispricing, despite its long-term potential to restore profitability. Thermo Fisher and argenx detracted from performance amid macro headwinds and lower-than...
Positive
Investopedia
28 days ago
Major U.S. equities indexes pushed higher at the top of the new trading week, bouncing back from declines posted ahead of the weekend. Although weaker-than-expected jobs data released on Friday raised concerns about the resilience of the economy, the slowdown in hiring and uptick in unemployment could add to the case for upcoming interest-rate cuts by the Federal Reserve.
Neutral
Seeking Alpha
28 days ago
IDEXX Laboratories, Inc. (NASDAQ:IDXX ) Q2 2025 Earnings Conference Call August 4, 2025 8:30 AM ET Company Participants Andrew Emerson - Executive VP, CFO & Treasurer Jonathan J. Mazelsky - President, CEO & Director Conference Call Participants Christopher Thomas Schott - JPMorgan Chase & Co, Research Division Daniel Christopher Clark - Leerink Partners LLC, Research Division David Michael West...
More IDEXX Laboratories News

Company Profile

IDEXX Laboratories, Inc. engages in the development, manufacture, and distribution of products and services for the animal veterinary, livestock and poultry, dairy and water testing markets. It operates through the following segments: CAG, Water, LPD, and Other. The CAG segment develops, designs, manufactures, and distributes products and performs services for veterinarians and the biomedical analytics market, primarily related to diagnostics and information management. The Water segment develops, designs, manufactures, and distributes a range of products used in the detection of various microbiological parameters in water. The LPD segment develops, designs, manufactures, and distributes diagnostic tests and related instrumentation and performs services, which are used to manage the health status of livestock and poultry, to improve producer, and to ensure the quality and safety of milk and food. The Other operating segment combines and presents products for the human point-of-care medical diagnostics market with its out-licensing arrangements. The company was founded by David Evans Shaw on December 19, 1983 and is headquartered in Westbrook, ME.

Head office United States
CEO Jonathan Mazelsky
Employees 11,000
Founded 1983
Website www.idexx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today